New combo therapy aims to shrink liver tumors before surgery
NCT ID NCT06994299
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 33 times
Summary
This early-phase study tests a new treatment for advanced liver cancer. Participants will receive focused radiation to the tumor along with two immunotherapy drugs (tremelimumab and durvalumab) to help the immune system fight the cancer. The goal is to see if this combination is safe and can shrink tumors enough to improve surgery results. The study was withdrawn before enrolling any participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
New York-Presbyterian Weill Cornell Medical College
New York, New York, 11355, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.